

Appl. No. 09/488,728
RCE filed October 25, 2004

2. **Amendments to the Claims**

This listing of claims will replace all prior versions and listings of claims in the application:

1-12 (*Cancelled*)

13. (*Currently amended*) A method of treating a mammal afflicted with ulcerative colitis, the method comprising administering to said animal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein is selected from the group consisting of:

- (a) a protein comprising amino acids 28 through 320 of SEQ ID NO:4;
- (b) a protein comprising an amino acid sequence that is at least 80% identical to the amino acid sequence of (a) that binds IL-17; and
- (c) a fragment of (a) that binds IL-17.

14. (*Cancelled*)

15. (*Withdrawn*) A method of treating a mammal afflicted with diabetes, the method comprising administering to said mammal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier.

16. (*Withdrawn*) The method according to claim 15, wherein the soluble IL-17R protein is selected from the group consisting of:

- (a) a protein comprising amino acids 1 through 322 of SEQ ID NO:2;
- (b) a protein comprising amino acids 1 through 320 of SEQ ID NO:4;
- (c) a protein having an amino acid sequence that is at least about 70% identical to the amino acid sequences of the proteins of (a) or (b) that binds IL-17; and
- (d) fragments of the proteins of (a), (b) or (c) that bind IL-17.

17. (*Currently amended*) A method of treating a mammal afflicted with Crohn's disease, the method comprising administering to said mammal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein is selected from the group consisting of:

Appl. No. 09/488,728
RCE filed October 25, 2004

- (a) a protein comprising amino acids 28 through 320 of SEQ ID NO:4;
- (b) a protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of (a) that binds IL-17; and
- (c) a fragment of (a) that binds IL-17.

18. *(Cancelled)*

19. *(New)* A method of treating a mammal afflicted with ulcerative colitis, the method comprising administering to said animal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein comprises amino acids 28 through 320 of SEQ ID NO:4.

20. *(New)* A method of treating a mammal afflicted with ulcerative colitis, the method comprising administering to said animal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein comprises a protein having an amino acid sequence that is at least 80% identical to amino acids 28 through 320 of SEQ ID NO:4 and binds IL-17.

21. *(New)* A method of treating a mammal afflicted with ulcerative colitis, the method comprising administering to said animal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein comprises a fragment of amino acids 28 through 320 of SEQ ID NO:4 that binds IL-17.

22. *(New)* The method according to claim 13, wherein the soluble IL-17R protein further comprises an Fc domain.

23. *(New)* The method according to claim 13, wherein the soluble IL-17R protein further comprises an oligomerizing domain.

24. *(New)* A method of treating a mammal afflicted with Crohn's disease, the method comprising administering to said mammal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein comprises amino acids 28 through 320 of SEQ ID NO:4.

Appl. No. 09/488,728
RCE filed October 25, 2004

25. (New) A method of treating a mammal afflicted with Crohn's disease, the method comprising administering to said mammal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein comprises a protein having an amino acid sequence that is at least 80% identical to amino acids 28 through 320 of SEQ ID NO:4 and binds IL-17.

26. (New) A method of treating a mammal afflicted with Crohn's disease, the method comprising administering to said mammal an effective amount of a soluble Interleukin-17 Receptor (IL-17R) protein and a pharmaceutically acceptable diluent or carrier, wherein the soluble IL-17R protein comprises a fragment of amino acids 28 through 320 of SEQ ID NO:4 that binds IL-17.

27. (New) The method according to claim 17, wherein the soluble IL-17R protein further comprises an Fc domain.

28. (New) The method according to claim 17, wherein the soluble IL-17R protein further comprises an oligomerizing domain.